Lyme Disease Support 2

Argentum Nitricum, Astragalus Menziesii, Calcarea Sulphurica, Cuprum Arsenicosum, Dna, Ferrum Phosphoricum, Kali Muriaticum, Kali Sulphuricum, Ledum Palustre, Magnesia Phosphorica, Rna, Silicea.


Ohm Pharma Inc.
Human Otc Drug
NDC 66096-723
Lyme Disease Support 2 also known as Argentum Nitricum, Astragalus Menziesii, Calcarea Sulphurica, Cuprum Arsenicosum, Dna, Ferrum Phosphoricum, Kali Muriaticum, Kali Sulphuricum, Ledum Palustre, Magnesia Phosphorica, Rna, Silicea. is a human otc drug labeled by 'Ohm Pharma Inc.'. National Drug Code (NDC) number for Lyme Disease Support 2 is 66096-723. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Lyme Disease Support 2 drug includes Astragalus Nuttallii Leaf - 3 [hp_X]/59mL Calcium Sulfate Anhydrous - 6 [hp_X]/59mL Cupric Arsenite - 12 [hp_X]/59mL Ferrosoferric Phosphate - 6 [hp_X]/59mL Herring Sperm Dna - 4 [hp_C]/59mL Magnesium Phosphate, Dibasic Trihydrate - 6 [hp_X]/59mL Potassium Chloride - 6 [hp_X]/59mL Potassium Sulfate - 6 [hp_X]/59mL Rhododendron Tomentosum Leafy Twig - 1 [hp_M]/59mL Saccharomyces Cerevisiae Rna - 4 [hp_C]/59mL and more. The currest status of Lyme Disease Support 2 drug is Active.

Drug Information:

Drug NDC: 66096-723
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Lyme Disease Support 2
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Argentum Nitricum, Astragalus Menziesii, Calcarea Sulphurica, Cuprum Arsenicosum, Dna, Ferrum Phosphoricum, Kali Muriaticum, Kali Sulphuricum, Ledum Palustre, Magnesia Phosphorica, Rna, Silicea.
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Ohm Pharma Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ASTRAGALUS NUTTALLII LEAF - 3 [hp_X]/59mL
CALCIUM SULFATE ANHYDROUS - 6 [hp_X]/59mL
CUPRIC ARSENITE - 12 [hp_X]/59mL
FERROSOFERRIC PHOSPHATE - 6 [hp_X]/59mL
HERRING SPERM DNA - 4 [hp_C]/59mL
MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE - 6 [hp_X]/59mL
POTASSIUM CHLORIDE - 6 [hp_X]/59mL
POTASSIUM SULFATE - 6 [hp_X]/59mL
RHODODENDRON TOMENTOSUM LEAFY TWIG - 1 [hp_M]/59mL
SACCHAROMYCES CEREVISIAE RNA - 4 [hp_C]/59mL
SILICON DIOXIDE - 6 [hp_X]/59mL
SILVER NITRATE - 6 [hp_X]/59mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 20 Nov, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 06 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:OHM PHARMA INC.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0366096723057
UPC stands for Universal Product Code.
UNII:NC1P15G4KZ
E934B3V59H
SK8L60BCSQ
91GQH8I5F7
51FI676N6F
HF539G9L3Q
660YQ98I10
1K573LC5TV
877L01IZ0P
J17GBZ5VGX
ETJ7Z6XBU4
95IT3W8JZE
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Blood Coagulation Factor [EPC]
Calcium [CS]
Calculi Dissolution Agent [EPC]
Cations
Divalent [CS]
Increased Coagulation Factor Activity [PE]
Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]
Magnesium Ion Exchange Activity [MoA]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
Potassium Compounds [CS]
Potassium Salt [EPC]
Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
66096-723-0559 mL in 1 BOTTLE, DROPPER (66096-723-05)20 Nov, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Supports the immune systems response to lyme disease symptoms.

Product Elements:

Lyme disease support 2 argentum nitricum, astragalus menziesii, calcarea sulphurica, cuprum arsenicosum, dna, ferrum phosphoricum, kali muriaticum, kali sulphuricum, ledum palustre, magnesia phosphorica, rna, silicea. alcohol glycerin water silver nitrate silver cation astragalus nuttallii leaf astragalus nuttallii leaf calcium sulfate anhydrous calcium cation cupric arsenite cupric cation herring sperm dna herring sperm dna ferrosoferric phosphate ferrosoferric phosphate potassium chloride potassium cation potassium sulfate potassium cation rhododendron tomentosum leafy twig ledum palustre twig magnesium phosphate, dibasic trihydrate magnesium cation saccharomyces cerevisiae rna saccharomyces cerevisiae rna silicon dioxide silicon dioxide

Indications and Usage:

Uses: supports the immune systems response to lyme disease symptoms.* * ​claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Warnings:

Warnings: if pregnant or breast-feeding, ask a health care professional before use. if symptoms worsen or persist for more than a week, discontinue use and contact a doctor. ​keep out of reach of children.

Dosage and Administration:

Directions: shake bottle 10 times prior to each use. adults & children above 12 years of age: take 10 drops under the tongue 3 times per day or as directed by a health care practioner. children under 12: consult a health care provider.

Package Label Principal Display Panel:

Homeopathic medicine ndc: 66096-723-05 lyme disease support #2 natural - safe - effective no side effects 2 fl oz (59ml) / 15% alcohol product of usa 2oz bottle label supports the immune systems response to lyme disease symptoms.

Further Questions:

Mfg. by: ohm pharma, inc. mineral wells, tx 76067 www.ohmpharma.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.